Ogata Niwako, Kanda Teppei, Kawahata Mizuki, Ichikawa Takayasu, Matsumoto Yuki, Morimitsu Waka, Nishino Yukiko, Itoi Takamasa, Furumoto Kayo
Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, IN, USA.
Department of Comparative Animal Science, College of Life Science, Kurashiki University of Science and the Arts, Okayama, Japan.
Vet Anaesth Analg. 2017 Sep;44(5):1091-1100. doi: 10.1016/j.vaa.2017.06.005. Epub 2017 Jul 3.
To determine the effects of brimonidine tartrate ophthalmic solution on sedation, heart rate (HR), respiratory frequency (f), rectal temperature (RT) and noninvasive mean arterial pressure (MAP) in healthy cats.
Randomized, blinded crossover study, with 1 week washout between treatments.
Six healthy purpose-bred cats.
Brimonidine tartrate ophthalmic solution 0.1% (one or two drops; 58.6 ± 3.3 μg per drop) or a control solution (artificial tear solution) was administered to six healthy cats. Behavioural observations and measurements of HR, f, RT and MAP were recorded before and at 30, 60, 90, 120, 180, 240, 300 and 360 minutes after topical administration. Behavioural scores were analysed using Friedman's test for repeated measures to evaluate the time effect in each treatment and treatment effect at each time point. Physiological variables (HR, f, RT and MAP) were analysed using two-way analysis of variance for repeated measures to evaluate the time and treatment effects. The level of significance was set at p < 0.05.
Dose-dependent behavioural and physiological responses were noted. A dose of two drops of brimonidine resulted in sedation in the cats and decreased HR and MAP. Significant sedative effects occurred between 30 and 120 minutes and for physiological responses up to 360 minutes. The most frequent adverse reaction was vomiting, occurring within 40 minutes in all six cats administered two drops and five of the six cats administered one drop of brimonidine.
The results demonstrated that ocular administration of brimonidine 0.1% ophthalmic solution induced sedation in cats and some cardiovascular effects usually associated with α-adrenoceptor agonists. Further studies should be performed to determine clinical applications for this agent in cats.
确定0.1%酒石酸溴莫尼定滴眼液对健康猫的镇静作用、心率(HR)、呼吸频率(f)、直肠温度(RT)和无创平均动脉压(MAP)的影响。
随机、双盲交叉研究,各治疗之间有1周的洗脱期。
6只健康的定向培育猫。
给6只健康猫滴入0.1%酒石酸溴莫尼定滴眼液(1滴或2滴;每滴58.6±3.3μg)或对照溶液(人工泪液溶液)。在局部给药前以及给药后30、60、90、120、180、240、300和360分钟记录行为观察结果以及HR、f、RT和MAP的测量值。使用Friedman重复测量检验分析行为评分,以评估每种治疗中的时间效应以及每个时间点的治疗效应。使用重复测量的双向方差分析分析生理变量(HR、f、RT和MAP),以评估时间和治疗效应。显著性水平设定为p<0.05。
观察到剂量依赖性的行为和生理反应。2滴酒石酸溴莫尼定的剂量可使猫镇静,并降低HR和MAP。在30至120分钟之间出现显著的镇静作用,生理反应可持续至360分钟。最常见的不良反应是呕吐,在滴入2滴酒石酸溴莫尼定的所有6只猫以及滴入1滴的6只猫中的5只中,均在40分钟内出现呕吐。
结果表明,眼部滴入0.1%酒石酸溴莫尼定滴眼液可使猫镇静,并产生一些通常与α-肾上腺素能受体激动剂相关的心血管效应。应进行进一步研究以确定该药物在猫中的临床应用。